Smoking Cessation in Chronic Obstructive Pulmonary Disease
Smoking cessation is the most effective strategy for slowing down the progression of chronic obstructive pulmonary disease (COPD) and reducing mortality in the approximately 50% of patients with diagnosed COPD who continue to smoke. While behavioral interventions (including simple advice) have modes...
Saved in:
Published in | Seminars in respiratory and critical care medicine Vol. 36; no. 4; p. 491 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
United States
01.08.2015
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Smoking cessation is the most effective strategy for slowing down the progression of chronic obstructive pulmonary disease (COPD) and reducing mortality in the approximately 50% of patients with diagnosed COPD who continue to smoke. While behavioral interventions (including simple advice) have modest efficacy in improving smoking quit rates, the combination of counseling and pharmacotherapy is more effective than either alone. When combined with even brief counseling, nicotine replacement therapy (NRT), bupropion SR, and varenicline have all been shown to be effective in promoting smoking cessation and sustained abstinence in smokers with COPD to a degree comparable to that observed in the general smoking population. However, the recidivism rate is high after initial quitting so that at the end of 1 year, approximately 80% or more of patients are still smoking. Thus, new approaches to smoking cessation are needed. One approach is to combine different pharmacotherapies, for example, nicotine patch plus rapidly acting NRT (e.g., gum or nasal spray) and/or bupropion or even varenicline plus either NRT or bupropion, in a stepwise approach over a varying duration depending on the severity of nicotine dependence and nicotine withdrawal symptoms during the quit attempt, as proposed in the American College of Chest Physicians Tobacco Dependence Took Kit. Electronic (e)-cigarettes, which deliver vaporized nicotine without most of the noxious components in the smoke from burning tobacco cigarettes, also has potential efficacy as a smoking cessation aid, but their efficacy and safety as either substitutes for regular cigarettes or smoking cessation aids require additional study. This task is complicated because e-cigarettes are currently unregulated and hundreds of different brands are currently available. |
---|---|
AbstractList | Smoking cessation is the most effective strategy for slowing down the progression of chronic obstructive pulmonary disease (COPD) and reducing mortality in the approximately 50% of patients with diagnosed COPD who continue to smoke. While behavioral interventions (including simple advice) have modest efficacy in improving smoking quit rates, the combination of counseling and pharmacotherapy is more effective than either alone. When combined with even brief counseling, nicotine replacement therapy (NRT), bupropion SR, and varenicline have all been shown to be effective in promoting smoking cessation and sustained abstinence in smokers with COPD to a degree comparable to that observed in the general smoking population. However, the recidivism rate is high after initial quitting so that at the end of 1 year, approximately 80% or more of patients are still smoking. Thus, new approaches to smoking cessation are needed. One approach is to combine different pharmacotherapies, for example, nicotine patch plus rapidly acting NRT (e.g., gum or nasal spray) and/or bupropion or even varenicline plus either NRT or bupropion, in a stepwise approach over a varying duration depending on the severity of nicotine dependence and nicotine withdrawal symptoms during the quit attempt, as proposed in the American College of Chest Physicians Tobacco Dependence Took Kit. Electronic (e)-cigarettes, which deliver vaporized nicotine without most of the noxious components in the smoke from burning tobacco cigarettes, also has potential efficacy as a smoking cessation aid, but their efficacy and safety as either substitutes for regular cigarettes or smoking cessation aids require additional study. This task is complicated because e-cigarettes are currently unregulated and hundreds of different brands are currently available. |
Author | Tashkin, Donald P |
Author_xml | – sequence: 1 givenname: Donald P surname: Tashkin fullname: Tashkin, Donald P organization: Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26238637$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j0tLxDAYRYMozkO3LiV_oM6Xd-JO6mtgYAR1PaRpotFpMjSt4L-3oK7u5nLPuQt0nHLyCF0QuCIgxKpUAExURAghCRyhOQGjKwNcz9CilA8A0ALIKZpRSZmWTM3R9XOXP2N6w7UvxQ4xJxwTrt_7nKLD26YM_eiG-OXx07jvcrL9N76Nxdviz9BJsPviz_9yiV7v717qx2qzfVjXN5vKMWOGie-skJwqG4K3mhIrQ9NMvo0KSlhvGHUhqJa3RHKnWjU1nGu1IYo7Fjhdosvf3cPYdL7dHfrYTRq7_xP0BweoSUA |
CitedBy_id | crossref_primary_10_1186_s12974_022_02432_y crossref_primary_10_3389_ftox_2021_653569 crossref_primary_10_1371_journal_pone_0288783 crossref_primary_10_3897_rrpharmacology_8_75467 crossref_primary_10_1186_s12890_024_02948_4 crossref_primary_10_1016_j_ijnurstu_2022_104362 crossref_primary_10_2147_COPD_S280540 crossref_primary_10_1007_s10753_017_0541_5 crossref_primary_10_1177_2040622320961617 crossref_primary_10_1016_j_pneumo_2018_10_001 crossref_primary_10_3390_ijms22147272 crossref_primary_10_1016_j_arbres_2016_01_015 crossref_primary_10_1177_17534666241239455 crossref_primary_10_1186_s12931_016_0481_x crossref_primary_10_1097_MD_0000000000038161 crossref_primary_10_1016_j_amepre_2023_02_032 crossref_primary_10_3389_fmicb_2021_690600 crossref_primary_10_1007_s00408_019_00208_5 crossref_primary_10_1038_s41598_020_78242_0 crossref_primary_10_3389_fphar_2022_1012433 crossref_primary_10_1080_13696998_2023_2269748 crossref_primary_10_3390_jcm13010019 crossref_primary_10_7475_kjan_2015_27_6_665 crossref_primary_10_1016_j_arbr_2017_04_018 crossref_primary_10_1016_j_rmed_2023_107126 crossref_primary_10_4046_trd_2021_0141 crossref_primary_10_7554_eLife_74648 crossref_primary_10_7759_cureus_49371 crossref_primary_10_1016_j_chest_2022_02_003 crossref_primary_10_3390_healthcare6020047 crossref_primary_10_3389_fpsyt_2018_00672 crossref_primary_10_1016_j_chest_2021_10_046 crossref_primary_10_2147_COPD_S323616 crossref_primary_10_1097_MD_0000000000029261 crossref_primary_10_1177_1535370220904342 crossref_primary_10_3390_biomedicines12010107 crossref_primary_10_1177_0300060517721309 crossref_primary_10_1016_j_jons_2019_04_001 crossref_primary_10_1016_j_arbr_2016_06_017 crossref_primary_10_2169_internalmedicine_1111_18 crossref_primary_10_3389_fmed_2022_927607 crossref_primary_10_18332_tid_90665 crossref_primary_10_1080_10799893_2020_1738483 crossref_primary_10_2147_COPD_S438686 crossref_primary_10_1186_s13722_021_00284_0 crossref_primary_10_1093_ntr_ntae072 crossref_primary_10_1186_s12890_023_02668_1 crossref_primary_10_1513_AnnalsATS_202104_463OC crossref_primary_10_1111_jebm_12570 crossref_primary_10_1007_s11739_021_02674_3 crossref_primary_10_1016_j_ccm_2020_06_013 crossref_primary_10_1080_10937404_2023_2208886 crossref_primary_10_1080_17476348_2023_2167716 crossref_primary_10_3390_pharmacy9030119 crossref_primary_10_1007_s43450_022_00331_0 crossref_primary_10_1089_jamp_2023_0016 crossref_primary_10_1016_j_arbres_2017_04_012 |
ContentType | Journal Article |
Copyright | Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA. |
Copyright_xml | – notice: Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA. |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1055/s-0035-1555610 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1098-9048 |
ExternalDocumentID | 26238637 |
Genre | Journal Article Review |
GroupedDBID | --- .GJ 0R~ 123 1KJ 34G 39C 4.4 53G 5RE 5~~ AAIWL AAKAS AAQQT AAWTL ABJNI ABOCM ABZLV ACGFS ADZCM AENEX AEVEF AHRAW AHRSK AIVKU AJGCD AKJTW ALMA_UNASSIGNED_HOLDINGS BPGNG C45 CAG CGR COF CS3 CUY CVF DU5 EBS ECM EIF EJD EXEOM F5P H13 IY8 J5H N4W N9A NPM O9- OVD Q3R QTC RIG ROL RTC TEORI YFH ZGI ZXP |
ID | FETCH-LOGICAL-c399t-90ca56427affea821a6fbb055b7f75ae932cff7d4d164c7d721accd89174c3f42 |
IngestDate | Sat Sep 28 08:03:03 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c399t-90ca56427affea821a6fbb055b7f75ae932cff7d4d164c7d721accd89174c3f42 |
PMID | 26238637 |
ParticipantIDs | pubmed_primary_26238637 |
PublicationCentury | 2000 |
PublicationDate | 2015-08-01 |
PublicationDateYYYYMMDD | 2015-08-01 |
PublicationDate_xml | – month: 08 year: 2015 text: 2015-08-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Seminars in respiratory and critical care medicine |
PublicationTitleAlternate | Semin Respir Crit Care Med |
PublicationYear | 2015 |
SSID | ssj0008501 |
Score | 2.3815193 |
SecondaryResourceType | review_article |
Snippet | Smoking cessation is the most effective strategy for slowing down the progression of chronic obstructive pulmonary disease (COPD) and reducing mortality in the... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 491 |
SubjectTerms | Combined Modality Therapy Counseling - methods Electronic Nicotine Delivery Systems - methods Humans Nicotine - pharmacology Nicotinic Agonists - pharmacology Pulmonary Disease, Chronic Obstructive - etiology Pulmonary Disease, Chronic Obstructive - prevention & control Secondary Prevention - methods Smoking - adverse effects Smoking - therapy Smoking Cessation - methods Treatment Outcome Varenicline - pharmacology |
Title | Smoking Cessation in Chronic Obstructive Pulmonary Disease |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26238637 |
Volume | 36 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELVYJMQFse_IB24okKZ27HJDLKqQWg5tpd4q27EFgqaVWnHg6xkvSUNZBOQQRXES2fOSyYw98wahU143HAxdcEsybiIiTBxJYXhkDOhLFae64RKFW-202SP3fdqfFf5z2SVTea7evswr-Q-qcA5wtVmyf0C2fCicgGPAF_aAMOx_hXFnOHp26_a2jkkRtRjobs8eZOCGfbVBOS_QKRsgd1NZkAk2acfyi4B_61NbZivvLuOtqITgIsTmF-K7YvIYynn5OeaQLRZmEWq0jGGDn4DXfJZYtBF72stCNXpukvAKkIqeI77E1if9G1NLVTGJHBMmmCrWOqteCPIbDx0aCdhdPPWELz-3zvFhF02LaJFxq9Padn4m_Hs5jWsFNSelFx87Yomfw81zToQzJrrraC14AfjKQ7qBFnS-iVZaQbxb6DIgi0tk8VOOA7K4giwukcUB2W3Uu7vtXjejUOUiUmAcTkHmSlDwApkwRgue1ERqpITeS2YYFRoMbGUMy0gGnq1iGbjsQqmMg59NVN2QZAct5aNc7yHMTcKkpFQQJUii7UhhvJrFGjaWJfto1496MPZUJoNCHgffthyi1dn7coSWDXw7-hgMsak8cbJ_B6xlM5E |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Smoking+Cessation+in+Chronic+Obstructive+Pulmonary+Disease&rft.jtitle=Seminars+in+respiratory+and+critical+care+medicine&rft.au=Tashkin%2C+Donald+P&rft.date=2015-08-01&rft.eissn=1098-9048&rft.volume=36&rft.issue=4&rft.spage=491&rft_id=info:doi/10.1055%2Fs-0035-1555610&rft_id=info%3Apmid%2F26238637&rft_id=info%3Apmid%2F26238637&rft.externalDocID=26238637 |